Merck KGaA seeks approval for Erbitux for colorectal cancer in Japan |
|
|
|
Published
:
Mon, 05 Feb 2007 08:41
|
FRANKFURT (AFX) - Merck KGaA's Merck Serono division said an application has been submitted by Merck Ltd Japan and ImClone Systems Inc to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Erbitux in treating patients with advanced colorectal cancer.Colorectal cancer is now the third biggest cancer threat in Japan -- taking the lives of more than 38,000 people annually -- following lung and stomach cancer, said a company statement.krysia.diver@afxnews.comkd/gpCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Merck KGaA's Erbitux hits primary endpoint in phase III colorectal cancer study 